Regeneron Pharmaceuticals, Inc. (REGN) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है Tarrytown, NY, United States. वर्तमान CEO हैं Leonard S. Schleifer.
REGN के पास है IPO तिथि 1991-04-02, 15,158 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Global Select, बाजार पूंजीकरण $78.5B.
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative medicines for serious diseases. The company's marketed portfolio includes EYLEA for retinal diseases, Dupixent for atopic dermatitis and asthma, Libtayo for cutaneous squamous cell carcinoma, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and several other specialized therapies for infectious, rare, and cancerous conditions. Regeneron maintains extensive collaboration agreements with leading pharmaceutical and biotechnology companies including Sanofi, Bayer, Roche, and AstraZeneca, as well as strategic partnerships with research institutions and government health agencies. Founded in 1988 and headquartered in Tarrytown, New York, the company focuses on high-value therapeutic areas including ophthalmology, immunology, cardiovascular disease, and oncology.
